Developer docs
API playgroundTry for free, no card

Search company profiles

NKA Bio

Full company profile

uuid0004udu

Namestring
NKA Bio
Legal namestring
NKA Bio, Inc.
Websiteurl
nkabio.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

NKA Bio is a private biotechnology startup founded in 2023 and headquartered in Baltimore, Maryland, that develops monoclonal antibody therapeutics for trauma care. The company's lead program, NKA01, is an anti-shock toxin antibody formulated as a prefilled syringe designed for administration by emergency medical services (EMS) at the point of injury to stabilize hemorrhagic shock patients during transport to trauma centers. The therapeutic approach targets the body's lethal shock response to injury rather than the underlying trauma. The technology is grounded in decades of NIH-funded research by the late Dr. Donald S. Gann, the first Director of Emergency Medicine at Johns Hopkins.

The company operates from Lab 317 at the LifeBridge Health BioIncubator in Baltimore, with R&D facilities equipped for antibody engineering and assay development supported by an in silico platform led by CTO Lewis C. Hibbs III. NKA01 is currently at the proof-of-concept in vivo stage with a lead candidate selected, and the company has stated a target to enter the clinic within 18 months. The clinical advisory bench includes Dr. Ernest E. Moore (trauma and clinical trials) and Dr. Jack Ingari (military medicine).

The business model is currently grant-driven and non-dilutive, with revenue consisting of a $1.25M AFWERX SBIR Phase II contract awarded in November 2025 plus a prior smaller round. Future commercial revenue is expected from sales of NKA01 to U.S. military medical services, civilian EMS systems, and hospital trauma centers, with a planned pipeline expansion involving the World Health Organization for global health applications. The company is led by CEO Susan Gann Hibbs and CTO Lewis C. Hibbs III, with regulatory and CMC leadership from Les E. Johnson.

Short descriptiontext

NKA Bio is a Baltimore-based biotech startup developing NKA01, a monoclonal antibody anti-shock treatment delivered via prefilled syringe for administration by EMS at the point of injury to stabilize hemorrhagic shock patients during transport to trauma centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapy, hemorrhagic shock treatment, prehospital trauma resuscitation, biopharmaceutical drug development, anti-shock antibody therapeutics
Industry2 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals — Trauma Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Government/Defense Contracts
TypeOthers
Description

Revenue from SBIR (Small Business Innovation Research) contracts with defense agencies like AFWERX for development of trauma treatments for military applications. Currently $1.25M AFWERX Phase II contract.

nkabio.com
2Pharmaceutical Product Sales
TypeOne Time License
Description

Future revenue from sale of NKA01 monoclonal antibody treatment to hospitals, trauma centers, and EMS systems for civilian and military trauma care.

nkabio.com
3SBIR Phase Contracts
TypeOthers
Description

Non-dilutive funding through Small Business Innovation Research (SBIR) program with AFWERX for developing lifesaving treatments for hemorrhagic shock.

einpresswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NKA Bio develops NKA01, a monoclonal antibody therapeutic delivered in a temperature-stable, prefilled syringe designed to treat hemorrhagic shock at the point of injury. The product is intended for use by military medics and civilian EMS personnel in prehospital settings, addressing the underlying shock response to buy critical time before surgical intervention. The company is advancing NKA01 through preclinical and clinical milestones, supported by an AFWERX SBIR Phase II contract from the U.S. Air Force.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90,000 trauma patients die annually before reaching hospital
+2 more records
Product overview1 text field

NKA Bio is a single-product biotech company developing NKA01, a monoclonal antibody (mAb) therapeutic for trauma care. NKA01 is a prefilled syringe formulation of an anti-shock toxin antibody designed for field administration by EMS during standard treatment protocols. The product aims to stabilize trauma patients experiencing hemorrhagic shock at the point of injury, buying critical time for transport to definitive care. Development is currently at proof-of-concept in vivo stage with a prototype, with lead candidate selected and path to clinic targeted within 18 months.

Product and service1 record
1NKA01
CategoryBiopharmaceuticals — Trauma Therapeutics (Monoclonal Antibody)
Description

NKA01 is a monoclonal antibody therapeutic delivered in a temperature-stable, prefilled syringe designed to treat hemorrhagic shock at the point of injury. It is intended for administration by military medics and civilian EMS personnel in prehospital settings, targeting the underlying shock biology to extend the window before surgical intervention. The product is being advanced toward clinical and regulatory milestones under an AFWERX SBIR Phase II contract from the U.S. Air Force.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

NKA Bio selected for Techstars Industries of the Future Accelerator Cohort 3, gaining mentorship, Demo Day exposure, and connections to investors and industry partners. Participated in Knoxville community introduction events.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

NKA Bio operates from LifeBridge Health BioIncubator Lab 317 in Baltimore, gaining access to healthcare ecosystem, lab facilities, and clinical expertise. LifeBridge Health is a major regional health system.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

NKA Bio is working with WHO as part of its pipeline development strategy, indicating potential for global health applications of the trauma treatment technology.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers6 records
TypeBroad incumbent
Description

Italian plasma-products company manufacturing biological therapeutics (plasma-derived coagulation factors, immunoglobulins) used in trauma, emergency, and critical care settings. Comparable to NKA Bio as a developer/manufacturer of biological therapies for trauma indications.

TypeBroad incumbent
Description

Global producer of plasma-derived and recombinant biological products including coagulation factors used in trauma and emergency surgery. Comparable to NKA Bio as a major biological therapeutics manufacturer with overlapping trauma-care use cases.

TypeBroad incumbent
Description

World-leading plasma-derived and recombinant biologics franchise within CSL Limited, with broad trauma, critical care, and bleeding emergency products. Comparable to NKA Bio as an established biological therapeutics company operating in trauma and emergency medicine channels.

TypeBroad incumbent
Description

Major global plasma fractionator producing biological therapies (immunoglobulins, coagulation products) for trauma, critical care, and emergency indications. Comparable to NKA Bio as a plasma/biological therapeutics manufacturer with overlap in trauma and emergency end markets.

TypeBroad incumbent
Description

Developer of biologic (mAb and recombinant protein) therapies for rare, immune-mediated, and life-threatening conditions including complement-mediated critical illness. Comparable to NKA Bio as a developer of monoclonal antibody / biologic therapeutics for acute, critical indications.

TypeEmerging player
Description

Clinical-stage biotech commercializing recombinant protein (biologic) therapies for rare and acute indications, including acute hereditary angioedema attacks. Comparable to NKA Bio as a clinical-stage biotech commercializing biologic therapeutics for acute, life-threatening events.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NKA Bio

Biopharmaceuticals — Trauma Therapeuticsnkabio.com

NKA Bio is a Baltimore-based biotech startup developing NKA01, a monoclonal antibody anti-shock treatment delivered via prefilled syringe for administration by EMS at the point of injury to stabilize hemorrhagic shock patients during transport to trauma centers.

What NKA Bio does

NKA Bio is a private biotechnology startup founded in 2023 and headquartered in Baltimore, Maryland, that develops monoclonal antibody therapeutics for trauma care. The company's lead program, NKA01, is an anti-shock toxin antibody formulated as a prefilled syringe designed for administration by emergency medical services (EMS) at the point of injury to stabilize hemorrhagic shock patients during transport to trauma centers. The therapeutic approach targets the body's lethal shock response to injury rather than the underlying trauma. The technology is grounded in decades of NIH-funded research by the late Dr. Donald S. Gann, the first Director of Emergency Medicine at Johns Hopkins.

The company operates from Lab 317 at the LifeBridge Health BioIncubator in Baltimore, with R&D facilities equipped for antibody engineering and assay development supported by an in silico platform led by CTO Lewis C. Hibbs III. NKA01 is currently at the proof-of-concept in vivo stage with a lead candidate selected, and the company has stated a target to enter the clinic within 18 months. The clinical advisory bench includes Dr. Ernest E. Moore (trauma and clinical trials) and Dr. Jack Ingari (military medicine).

The business model is currently grant-driven and non-dilutive, with revenue consisting of a $1.25M AFWERX SBIR Phase II contract awarded in November 2025 plus a prior smaller round. Future commercial revenue is expected from sales of NKA01 to U.S. military medical services, civilian EMS systems, and hospital trauma centers, with a planned pipeline expansion involving the World Health Organization for global health applications. The company is led by CEO Susan Gann Hibbs and CTO Lewis C. Hibbs III, with regulatory and CMC leadership from Les E. Johnson.

NKA Bio firmographics

Firmographics
Name
NKA Bio
Legal name
NKA Bio, Inc.
Website
https://nkabio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
NKA Bio is a Baltimore-based biotech startup developing NKA01, a monoclonal antibody anti-shock treatment delivered via prefilled syringe for administration by EMS at the point of injury to stabilize hemorrhagic shock patients during transport to trauma centers.
Ownership category
akta.pro rank

NKA Bio industry classification

Industry
Product category
Biopharmaceuticals — Trauma Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Monoclonal antibody therapy
  • Hemorrhagic shock treatment
  • Prehospital trauma resuscitation
  • Biopharmaceutical drug development
  • Anti-shock antibody therapeutics

Where NKA Bio is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NKA Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Government/Defense Contracts: Revenue from SBIR (Small Business Innovation Research) contracts with defense agencies like AFWERX for development of trauma treatments for military applications. Currently $1.25M AFWERX Phase II contract.
  2. Pharmaceutical Product Sales: Future revenue from sale of NKA01 monoclonal antibody treatment to hospitals, trauma centers, and EMS systems for civilian and military trauma care.
  3. SBIR Phase Contracts: Non-dilutive funding through Small Business Innovation Research (SBIR) program with AFWERX for developing lifesaving treatments for hemorrhagic shock.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

NKA Bio product offering

Product offering

Core offering

NKA Bio develops NKA01, a monoclonal antibody therapeutic delivered in a temperature-stable, prefilled syringe designed to treat hemorrhagic shock at the point of injury. The product is intended for use by military medics and civilian EMS personnel in prehospital settings, addressing the underlying shock response to buy critical time before surgical intervention. The company is advancing NKA01 through preclinical and clinical milestones, supported by an AFWERX SBIR Phase II contract from the U.S. Air Force.

Product overview

NKA Bio is a single-product biotech company developing NKA01, a monoclonal antibody (mAb) therapeutic for trauma care. NKA01 is a prefilled syringe formulation of an anti-shock toxin antibody designed for field administration by EMS during standard treatment protocols. The product aims to stabilize trauma patients experiencing hemorrhagic shock at the point of injury, buying critical time for transport to definitive care. Development is currently at proof-of-concept in vivo stage with a prototype, with lead candidate selected and path to clinic targeted within 18 months.

Differentiator

Problem solved

Functional benefit

Products and services

  • NKA01 NKA01 is a monoclonal antibody therapeutic delivered in a temperature-stable, prefilled syringe designed to treat hemorrhagic shock at the point of injury. It is intended for administration by military medics and civilian EMS personnel in prehospital settings, targeting the underlying shock biology to extend the window before surgical intervention. The product is being advanced toward clinical and regulatory milestones under an AFWERX SBIR Phase II contract from the U.S. Air Force.

Quantifiable outcome

  • 90,000 trauma patients die annually before reaching hospital
  • +2 more outcomes

Companies that use NKA Bio

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

NKA Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NKA Bio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship, core and minor.

  • Techstars Industries of the Future AcceleratorflagshipStrategic or Co-development Partner · 1 January 2024NKA Bio selected for Techstars Industries of the Future Accelerator Cohort 3, gaining mentorship, Demo Day exposure, and connections to investors and industry partners. Participated in Knoxville community introduction events.
  • LifeBridge Health BioIncubatorcoreStrategic or Co-development Partner · 1 January 2024NKA Bio operates from LifeBridge Health BioIncubator Lab 317 in Baltimore, gaining access to healthcare ecosystem, lab facilities, and clinical expertise. LifeBridge Health is a major regional health system.
  • World Health Organization (WHO)minorStrategic or Co-development PartnerNKA Bio is working with WHO as part of its pipeline development strategy, indicating potential for global health applications of the trauma treatment technology.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

NKA Bio competitors and assessment

Company assessment

Broad incumbents

  • Kedrion Biopharma: Italian plasma-products company manufacturing biological therapeutics (plasma-derived coagulation factors, immunoglobulins) used in trauma, emergency, and critical care settings. Comparable to NKA Bio as a developer/manufacturer of biological therapies for trauma indications.
  • Octapharma: Global producer of plasma-derived and recombinant biological products including coagulation factors used in trauma and emergency surgery. Comparable to NKA Bio as a major biological therapeutics manufacturer with overlapping trauma-care use cases.
  • CSL Behring: World-leading plasma-derived and recombinant biologics franchise within CSL Limited, with broad trauma, critical care, and bleeding emergency products. Comparable to NKA Bio as an established biological therapeutics company operating in trauma and emergency medicine channels.
  • Grifols: Major global plasma fractionator producing biological therapies (immunoglobulins, coagulation products) for trauma, critical care, and emergency indications. Comparable to NKA Bio as a plasma/biological therapeutics manufacturer with overlap in trauma and emergency end markets.
  • Alexion (AstraZeneca Rare Disease): Developer of biologic (mAb and recombinant protein) therapies for rare, immune-mediated, and life-threatening conditions including complement-mediated critical illness. Comparable to NKA Bio as a developer of monoclonal antibody / biologic therapeutics for acute, critical indications.

Emerging players

  • Pharming Group: Clinical-stage biotech commercializing recombinant protein (biologic) therapies for rare and acute indications, including acute hereditary angioedema attacks. Comparable to NKA Bio as a clinical-stage biotech commercializing biologic therapeutics for acute, life-threatening events.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NKA Bio social profiles

Digital presence

NKA Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NKA Bio leadership team

Management profile

Number of profiles

Profiles5 records

NKA Bio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NKA Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NKA Bio

What does NKA Bio do?

NKA Bio develops NKA01, a monoclonal antibody therapeutic delivered in a temperature-stable, prefilled syringe designed to treat hemorrhagic shock at the point of injury. The product is intended for use by military medics and civilian EMS personnel in prehospital settings, addressing the underlying shock response to buy critical time before surgical intervention. The company is advancing NKA01 through preclinical and clinical milestones, supported by an AFWERX SBIR Phase II contract from the U.S. Air Force.

Is NKA Bio a public or private company?

NKA Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NKA Bio founded?

NKA Bio was founded in 2023. It employs 1 to 10 people.

Where is NKA Bio based?

NKA Bio is headquartered in Baltimore, United States, in the North America region.

How does NKA Bio make money?

Three revenue lines are on record. Government/Defense Contracts are the primary driver. The others are pharmaceutical Product Sales and SBIR Phase Contracts.

Who are NKA Bio's main competitors?

Broad incumbents on record are Kedrion Biopharma, Octapharma, CSL Behring, Grifols and Alexion (AstraZeneca Rare Disease). Pharming Group is listed as an emerging player.

Does NKA Bio have an API?

No public API is recorded for NKA Bio.

What industry is NKA Bio in?

NKA Bio's product category is Biopharmaceuticals — Trauma Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals